Pfizer and its German partner BioNTech said on Friday they have requested the U.S. Food and Drug Administration to expand the emergency use of their COVID-19 vaccine in adolescents aged 12 to 15.
In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.
Whether COVID-19 vaccines work and are safe to use on children is one of the big questions drugmakers are trying to answer. Inoculating children and young people is considered a critical step toward reaching “herd immunity” and taming the pandemic, according to experts.
- Nova Scotia aims to reduce mammogram wait times, enhance women’s health care
- Anthrax outbreak kills more than 50 animals, infects 12 people in Zambia
- Childhood Cancer Canada calls for $15M from feds as demand rises
- ‘E-dirt bikes are not toys’: E.R. doc fears more injuries after 2 kids hit in Edmonton
Get weekly health news
The companies plan to request similar rulings by other regulatory authorities globally in the coming days.
The Pfizer/BioNTech two-shot vaccine is already authorized for use in people as young as 16.
Comments
Want to discuss? Please read our Commenting Policy first.